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BACKGROUND
OBJECTIVES
METHODS
REFERENCES
 Cardiovascular disease is leading cause of death in 
people living with HIV (PLWH)
 HIV positive individuals have 1.5-2-fold greater risk of 
CVD, even if complete viral load suppression is achieved
 Chronic inflammation, immune dysregulation, or 
antiretroviral therapy (ART) specific risk factors are 
potential mechanisms of increased CVD risk
 HIV-associated cardiovascular disease (CVD) has tripled 
in past 20 years, but scant data is available about its long-
term characterization
Characterization of Cardiovascular Risk Factors of People Living with HIV in a 
Veteran Population
RESULTS
CONCLUSIONS
LIMITATIONS
 Characterize CVD risk factors and treatment in PLWH in 
order to assess and improve cardioprotective treatment 
in a veteran population 
 Retrospective review of electronic medical records was 
conducted on a patient list generated by TheraDoc
Clinical Surveillance Software that included all veterans 
treated with ART from December 1, 2018 – December 31, 
2019. 
 Exclusion Criteria:
 Lab results collected > 1 year from last HIV clinic     
follow-up
 Data Collected:
 Patient demographic information: age, sex, race, BMI
 HIV characterization and treatment: HIV VL, CD4 
count, ART therapy
 Hypertension characterization (BP readings) and 
treatment
 Diabetes characterization  (A1c, fasting glucose) and 
treatment 
 Dyslipidemia characterization and treatment
 Cardiovascular events: MI, CVD/Stent/CABG, Stroke, 
PVD, HF
 Additional data collection: smoking status, aspirin 
use, renal impairment
 Retrospective Review
 Data reliant on TheraDoc Clinical Surveillance Software 
and medical chart documentation accuracy
 Assessing cardiovascular risk using ACC ASCVD Risk 
Estimator has built-in limitations when calculating 10-
year ASCVD Risk including:
 Age must be 20-79
 LDL must be between 70 and 190
 TC must be at least 130
 HDL must be at least 20
 ASCVD risk estimator does not include any HIV-specific 
risk factors in their calculations
 Despite metabolic risk factors being near goal, our 
patient’s ASCVD risk was still high, likely due to 
uncontrolled diabetes, smoking status, BMI, and a large 
proportion of our patients being African American. 
 Calculated ASCVD is likely an underestimation of our 
patient’s true value due to a lack of HIV specific risk 
factors in the ASCVD Risk Estimator. 
 Characterization of CVD in PLWH should be a high 
priority and treatment should be closely monitored, due 
to their longer lifespans and the rising disease state 
burden. 
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Characterization of Metabolic Risk Factors
Average Range
BMI 29 16 – 66
LDL 90 16 – 204
HDL 51 19 – 117
Triglycerides 141 37 – 522
Glucose 108 61 – 449
A1c 6 3.6 – 14
SCr* 1.4 0.4 – 12.1
Blood Pressure Systolic 126 93 – 167Diastolic 76 42 – 101
10 – Year ASCVD Risk 25 6.9 – 56.4
* = median used in lieu of mean
Baseline Characteristics (n=242)
Age 58 (24 – 89)
Race
Black/African American
White
Other
77%
21%
2%
Smoking Status
Current
Former
Nonsmoker
33%
34%
33%
Diabetes
On Diabetes Medications
A1c < 7%
25%
76%
51%
Hypertension (HTN)
< 140/90
On HTN Medications
86%
50%
Lipid Control
LDL < 70
On Lipid Lowering Agent 
On Statin
40%
58%
56%
CD4 Count (units) 653             (14-2427)
HIV Viral Load (VL) (units) (average from last 2 
results)
< 20
< 200
59%
91%
Aspirin Use 39%
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